AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

AstraZeneca and Merck are racing against GlaxoSmithKline to snag an expanded nod for Lynparza in ovarian cancer patients who responded to their first round of chemo. And with a priority nod from the FDA, the partners just got a boost that could put them ahead.